A guide for functional analysis of BRCA1 variants of uncertain significance
暂无分享,去创建一个
Etienne Rouleau | Aneliya Velkova | Alvaro Galli | Michelle Webb | F. Couch | R. Brandão | M. Blok | S. Neuhausen | A. Monteiro | Melissa A. Brown | A. Galli | M. Vreeswijk | T. V. Hansen | E. Rouleau | S. Caputo | Aneliya Velkova | Maaike P.G. Vreeswijk | G. Millot | M. Webb | Sandrine M. Caputo | Fergus J. Couch | Melissa A. Brown | Gaël A. Millot | Marcelo A. Carvalho | Susan L. Neuhausen | Thomas v. O. Hansen | Rita D. Brandão | Marinus J. Blok | Alvaro N.A. Monteiro | Marcelo A. Carvalho | A. Monteiro
[1] Ana Kozomara,et al. miRBase: integrating microRNA annotation and deep-sequencing data , 2010, Nucleic Acids Res..
[2] I. Verma,et al. Transcriptional activation by BRCA1 , 1996, Nature.
[3] Andrej Sali,et al. Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis. , 2007, Cancer research.
[4] C. Deng,et al. Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155 , 2011, Nature Medicine.
[5] A. Nicolas,et al. Assessment of human nter and cter BRCA1 mutations using growth and localization assays in yeast , 2011, Human mutation.
[6] Christopher B. Burge,et al. Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals , 2003, RECOMB '03.
[7] Zhihui Feng,et al. DNA Damage Induces p53-dependent BRCA1 Nuclear Export* , 2004, Journal of Biological Chemistry.
[8] T. Ohta,et al. Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[9] J. Glover,et al. Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1 , 2004, Nature Structural &Molecular Biology.
[10] R. Wooster,et al. Gene Expression Profiling after Radiation-Induced DNA Damage Is Strongly Predictive of BRCA1 Mutation Carrier Status , 2004, Clinical Cancer Research.
[11] J. Glover,et al. Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays. , 2010, Cancer research.
[12] Chris M. Brown,et al. Transterm: a database to aid the analysis of regulatory sequences in mRNAs , 2008, Nucleic Acids Res..
[13] P. Goss,et al. Identification of a novel transcriptional repressor element located in the first intron of the human BRCA1 gene , 2001, Oncogene.
[14] Virna Dapić,et al. Functional implications of BRCA1 for early detection, prevention, and treatment of breast cancer. , 2006, Critical reviews in eukaryotic gene expression.
[15] N Risch,et al. Genetic analysis of breast cancer in the cancer and steroid hormone study. , 1991, American journal of human genetics.
[16] D. Livingston,et al. In search of the tumour-suppressor functions of BRCA1 and BRCA2 , 2000, Nature.
[17] Joshua E. Elias,et al. BRCA1-dependent ubiquitination of gamma-tubulin regulates centrosome number. , 2004, Molecular and cellular biology.
[18] A. Monteiro,et al. Epigenetic tumor suppression by BRCA1 , 2011, Nature Medicine.
[19] E. Chan,et al. Mutations in the BRCT Domain Confer Temperature Sensitivity to BRCA1 in Transcription Activation , 2002, Cancer biology & therapy.
[20] Melissa A. Brown,et al. Identification of two evolutionarily conserved and functional regulatory elements in intron 2 of the human BRCA1 gene. , 2005, Genomics.
[21] B. Henderson,et al. The BRCA1 RING and BRCT Domains Cooperate in Targeting BRCA1 to Ionizing Radiation-induced Nuclear Foci* , 2005, Journal of Biological Chemistry.
[22] M. MacCoss,et al. Estrogen receptor alpha is a putative substrate for the BRCA1 ubiquitin ligase. , 2007, Proceedings of the National Academy of Sciences of the United States of America.
[23] Thomas Ludwig,et al. The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity. , 2002, Current opinion in genetics & development.
[24] Fergus J Couch,et al. A review of a multifactorial probability‐based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS) , 2012, Human mutation.
[25] A. Spurdle,et al. Characterization of BRCA1 and BRCA2 splicing variants: a collaborative report by ENIGMA consortium members , 2012, Breast Cancer Research and Treatment.
[26] Chun-Fang Xu,et al. Regulation of BRCAl , 1994, Nature.
[27] Yigong Shi,et al. Structure of the BRCT repeats of BRCA1 bound to a BACH1 phosphopeptide: implications for signaling. , 2004, Molecular cell.
[28] Rachel E. Klevit,et al. Structure of a BRCA1–BARD1 heterodimeric RING–RING complex , 2001, Nature Structural Biology.
[29] L. Esserman,et al. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. , 2005, JAMA.
[30] P. van Oostveldt,et al. Phosphorylated BRCA1 is predominantly located in the nucleus and mitochondria. , 2004, Molecular biology of the cell.
[31] A. Horwitz,et al. BRCA1/BARD1 Ubiquitinate Phosphorylated RNA Polymerase II* , 2005, Journal of Biological Chemistry.
[32] D. F. Easton,et al. Genetic linkage analysis in familial breast and ovarian cancer: Results from 214 families , 1993 .
[33] F. Amaldi,et al. A somatic mutation in the 5′UTR of BRCA1 gene in sporadic breast cancer causes down-modulation of translation efficiency , 2001, Oncogene.
[34] S. Sharan,et al. Mouse embryonic stem cell–based functional assay to evaluate mutations in BRCA2 , 2008, Nature Medicine.
[35] R. Lidereau,et al. Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers , 2011, EMBO molecular medicine.
[36] Suhwan Chang,et al. Expression of human BRCA1 variants in mouse ES cells allows functional analysis of BRCA1 mutations. , 2009, The Journal of clinical investigation.
[37] T. Magliery,et al. Re-engineering a split-GFP reassembly screen to examine RING-domain interactions between BARD1 and BRCA1 mutants observed in cancer patients. , 2008, Molecular bioSystems.
[38] Stefan Schüchner,et al. Nuclear–cytoplasmic shuttling of BARD1 contributes to its proapoptotic activity and is regulated by dimerization with BRCA1 , 2004, Oncogene.
[39] Olufunmilayo I Olopade,et al. BRCA2 T2722R is a deleterious allele that causes exon skipping. , 2002, American journal of human genetics.
[40] F. Couch,et al. Functional assays for BRCA1 and BRCA2. , 2007, The international journal of biochemistry & cell biology.
[41] Georges Mer,et al. The BRCT Domain Is a Phospho-Protein Binding Domain , 2003, Science.
[42] Mark Girolami,et al. BRCA1 and BRCA2 Missense Variants of High and Low Clinical Significance Influence Lymphoblastoid Cell Line Post-Irradiation Gene Expression , 2008, PLoS genetics.
[43] Ivo L. Hofacker,et al. Vienna RNA secondary structure server , 2003, Nucleic Acids Res..
[44] Ralph Scully,et al. Dynamic Changes of BRCA1 Subnuclear Location and Phosphorylation State Are Initiated by DNA Damage , 1997, Cell.
[45] T. Ludwig,et al. BRCA 1 Tumor Suppression Depends on BRCT Phosphoprotein Binding , But Not Its E 3 Ligase Activity , 2014 .
[46] Sam W. Lee,et al. Tumor Suppressor p53 Is Required To Modulate BRCA1 Expression , 2000, Molecular and Cellular Biology.
[47] J. French,et al. Dynamic interactions between the promoter and terminator regions of the mammalian BRCA1 gene , 2008, Proceedings of the National Academy of Sciences.
[48] P. Møller,et al. Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families. , 2001, Human molecular genetics.
[49] F. Collins,et al. Human BRCA1 inhibits growth in yeast: potential use in diagnostic testing. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[50] J Chang-Claude,et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.
[51] J. Minna,et al. Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. , 1998, Cancer research.
[52] A. Spurdle,et al. Use of DNA–Damaging Agents and RNA Pooling to Assess Expression Profiles Associated with BRCA1 and BRCA2 Mutation Status in Familial Breast Cancer Patients , 2010, PLoS genetics.
[53] L. Matthews,et al. Accurate Prediction of BRCA1 and BRCA2 Heterozygous Genotype Using Expression Profiling after Induced DNA Damage , 2006, Clinical Cancer Research.
[54] Yonghong Xiao,et al. Association of BRCA1 with Rad51 in Mitotic and Meiotic Cells , 1997, Cell.
[55] D. Livingston,et al. Genetic analysis of BRCA1 function in a defined tumor cell line. , 1999, Molecular cell.
[56] Michael Zuker,et al. Mfold web server for nucleic acid folding and hybridization prediction , 2003, Nucleic Acids Res..
[57] Y. Chen,et al. BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner. , 1996, Cancer research.
[58] Fergus J Couch,et al. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. , 2007, American journal of human genetics.
[59] Junjie Chen,et al. Phosphopeptide Binding Specificities of BRCA1 COOH-terminal (BRCT) Domains* , 2003, Journal of Biological Chemistry.
[60] Maximina H. Yun,et al. Understanding the functions of BRCA1 in the DNA-damage response. , 2009, Biochemical Society transactions.
[61] A. Monteiro,et al. Yeast-based assays for detection and characterization of mutations in BRCA1. , 1998, Breast disease.
[62] Alun Thomas,et al. Classification of rare missense substitutions, using risk surfaces, with genetic‐ and molecular‐epidemiology applications , 2008, Human mutation.
[63] Sue Healey,et al. ENIGMA—Evidence‐based network for the interpretation of germline mutant alleles: An international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes , 2012, Human mutation.
[64] R. Baer,et al. The BRCA1/BARD1 Heterodimer Assembles Polyubiquitin Chains through an Unconventional Linkage Involving Lysine Residue K6 of Ubiquitin* , 2003, Journal of Biological Chemistry.
[65] Ben Lehner,et al. Predicting mutation outcome from early stochastic variation in genetic interaction partners , 2011, Nature.
[66] F. Couch,et al. Splicing and multifactorial analysis of intronic BRCA1 and BRCA2 sequence variants identifies clinically significant splicing aberrations up to 12 nucleotides from the intron/exon boundary , 2011, Human mutation.
[67] Steven E. Bayer,et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.
[68] C. Osborne,et al. Location of BRCA1 in Human Breast and Ovarian Cancer Cells , 1996, Science.
[69] A. Bowcock,et al. Cell cycle-dependent colocalization of BARD1 and BRCA1 proteins in discrete nuclear domains. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[70] E. Yang,et al. DNA damage-induced cytotoxicity is dissociated from BRCA1's DNA repair function but is dependent on its cytosolic accumulation. , 2010, Cancer research.
[71] K. Valerie,et al. Mutations in the BRCT binding site of BRCA1 result in hyper-recombination , 2011, Aging.
[72] B. Koller,et al. Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities , 1996, Nature Genetics.
[73] F. Couch,et al. Classification of missense substitutions in the BRCA genes: A database dedicated to Ex‐UVs , 2012, Human mutation.
[74] Steven P. Gygi,et al. BRCA1-Dependent Ubiquitination of γ-Tubulin Regulates Centrosome Number , 2004, Molecular and Cellular Biology.
[75] D. Chasman,et al. Detection of Protein Folding Defects Caused by BRCA1-BRCT Truncation and Missense Mutations* , 2003, Journal of Biological Chemistry.
[76] J. Rossant,et al. The Tumor Suppressor Gene Brca1 Is Required for Embryonic Cellular Proliferation in the Mouse , 1996, Cell.
[77] David J. Arenillas,et al. oPOSSUM: identification of over-represented transcription factor binding sites in co-expressed genes , 2005, Nucleic acids research.
[78] Etienne Rouleau,et al. Description and analysis of genetic variants in French hereditary breast and ovarian cancer families recorded in the UMD-BRCA1/BRCA2 databases , 2011, Nucleic Acids Res..
[79] H. Hanafusa,et al. Evidence for a transcriptional activation function of BRCA1 C-terminal region. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[80] Francesca Chiaromonte,et al. Evaluation of regulatory potential and conservation scores for detecting cis-regulatory modules in aligned mammalian genome sequences. , 2005, Genome research.
[81] A. Horwitz,et al. BRCA 1 / BARD 1 Ubiquitinate Phosphorylated RNA Polymerase II * , 2005 .
[82] Fergus J Couch,et al. A Computational Method to Classify Variants of Uncertain Significance Using Functional Assay Data with Application to BRCA1 , 2011, Cancer Epidemiology, Biomarkers & Prevention.
[83] C. Deng,et al. A targeted disruption of the murine Brca1 gene causes γ-irradiation hypersensitivity and genetic instability , 1998, Oncogene.
[84] Peter Bouwman,et al. BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. , 2011, Cancer cell.
[85] Chun-Fang Xu,et al. Complex Regulation of the BRCA1 Gene* , 1997, The Journal of Biological Chemistry.
[86] R. Birge,et al. A nuclear function for the tumor suppressor BRCA1. , 2000, Histology and histopathology.
[87] P. Glazer,et al. Basal repression of BRCA1 by multiple E2Fs and pocket proteins at adjacent E2F sites , 2006, Cancer biology & therapy.
[88] A. Kurian. BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications , 2010, Current opinion in obstetrics & gynecology.
[89] F. Couch,et al. Mutations and Polymorphisms in the familial early‐onset breast cancer (BRCA1) gene , 1996, Human mutation.
[90] T. Walsh,et al. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing , 2010, Proceedings of the National Academy of Sciences.
[91] Fred H. Gage,et al. BRCA1 tumor suppression occurs via heterochromatin mediated silencing , 2011, Nature.
[92] S. Elledge,et al. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. , 1999, Science.
[93] P. Irusta,et al. Identification of a functional nuclear export sequence in the apoptosis‐modulating protein Aven , 2007 .
[94] S. Friend,et al. Breast cancer information on the web , 1995, Nature Genetics.
[95] S. Macura,et al. Structural basis of BACH1 phosphopeptide recognition by BRCA1 tandem BRCT domains. , 2004, Structure.
[96] A. Spurdle,et al. Molecular characterization and cancer risk associated with BRCA1 and BRCA2 splice site variants identified in multiple‐case breast cancer families , 2005, Human mutation.
[97] S. Edwards,et al. Posttranscriptional regulation of the breast cancer susceptibility gene BRCA1 by the RNA binding protein HuR. , 2008, Cancer research.
[98] Chun-Fang Xu,et al. Germline BRCA1 promoter deletions in UK and Australian familial breast cancer patients: Identification of a novel deletion consistent with BRCA1:ψBRCA1 recombination , 2002, Human mutation.
[99] J. Parvin,et al. Functional differences among BRCA1 missense mutations in the control of centrosome duplication , 2012, Oncogene.
[100] S. Tavtigian,et al. Identification of Filamin A as a BRCA1-interacting protein required for efficient DNA repair , 2010, Cell cycle.
[101] F. Couch,et al. Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants? , 2007, Breast Cancer Research.
[102] F. Barany,et al. Classification of BRCA1 missense variants of unknown clinical significance , 2005, Journal of Medical Genetics.
[103] A. Galli,et al. A yeast recombination assay to characterize human BRCA1 missense variants of unknown pathological significance , 2009, Human mutation.
[104] S. Neuhausen,et al. Prevalence of BRCA Mutations and Founder Effect in High-Risk Hispanic Families , 2005, Cancer Epidemiology Biomarkers & Prevention.
[105] Sue Healey,et al. Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence variants encoding missense substitutions: implications for prediction of pathogenicity , 2010, Human mutation.
[106] R. Brent,et al. Correlation of two-hybrid affinity data with in vitro measurements , 1995, Molecular and cellular biology.
[107] A. Spurdle,et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results , 2008, Human mutation.
[108] R. Jensen,et al. BRCA1 Expression Restores Radiation Resistance in BRCA1-defective Cancer Cells through Enhancement of Transcription-coupled DNA Repair* , 1999, The Journal of Biological Chemistry.
[109] David Haussler,et al. Improved splice site detection in Genie , 1997, RECOMB '97.
[110] C. Szabo,et al. Understanding Germ-Line Mutations in BRCA1 , 2004, Cancer biology & therapy.
[111] S. Edwards,et al. Regulation of BRCA1 messenger RNA stability in human epithelial cell lines and during cell cycle progression , 2007, FEBS letters.
[112] D. Easton,et al. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. , 1993, American journal of human genetics.
[113] Chikashi Ishioka,et al. Identification of breast tumor mutations in BRCA1 that abolish its function in homologous DNA recombination. , 2010, Cancer research.
[114] J. Glover,et al. Structural Consequences of a Cancer-causing BRCA1-BRCT Missense Mutation* , 2003, The Journal of Biological Chemistry.
[115] Sean V Tavtigian,et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[116] E. Solomon,et al. Isolation and characterisation of the NBR2 gene which lies head to head with the human BRCA1 gene. , 1997, Human molecular genetics.
[117] T. Ludwig,et al. BRCA1 Tumor Suppression Depends on BRCT Phosphoprotein Binding, But Not Its E3 Ligase Activity , 2011, Science.
[118] F. Couch,et al. Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. , 2004, American journal of human genetics.
[119] S. Salzberg,et al. GeneSplicer: a new computational method for splice site prediction. , 2001, Nucleic acids research.
[120] J. Rommens,et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds , 1996, Nature Genetics.
[121] Julian Peto,et al. Identification of the breast cancer susceptibility gene BRCA2 , 1996, Nature.
[122] D. Papadopoulo,et al. A single mutated BRCA1 allele leads to impaired fidelity of double strand break end-joining , 2002, Oncogene.
[123] H. Ruffner,et al. Cancer-predisposing mutations within the RING domain of BRCA1: Loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[124] T. Katagiri,et al. Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility. , 2006, Human molecular genetics.
[125] M. MacCoss,et al. Estrogen receptor α is a putative substrate for the BRCA1 ubiquitin ligase , 2007, Proceedings of the National Academy of Sciences.
[126] J. Rodriguez,et al. Identification of a Functional Nuclear Export Sequence in BRCA1* , 2000, The Journal of Biological Chemistry.
[127] J. Trowsdale,et al. Regulation of BRCA1. , 1994, Nature.
[128] Michael Q. Zhang,et al. High-resolution human core-promoter prediction with CoreBoost_HM. , 2009, Genome research.
[129] W. Foulkes,et al. BRCA1 and BRCA2: 1994 and beyond , 2004, Nature Reviews Cancer.
[130] R. Hui,et al. A functional variant in the 3'-UTR of angiopoietin-1 might reduce stroke risk by interfering with the binding efficiency of microRNA 211. , 2010, Human molecular genetics.
[131] J. Glover,et al. Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1 , 2001, Nature Structural Biology.
[132] T. Ludwig,et al. E3 ligase activity of BRCA1 is not essential for mammalian cell viability or homology-directed repair of double-strand DNA breaks , 2008, Proceedings of the National Academy of Sciences.
[133] Drew M. Lowery,et al. Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer , 2004, Nature Structural &Molecular Biology.
[134] Lawrence C. Brody,et al. Functional Characterization of BRCA1 Sequence Variants using a Yeast Small Colony Phenotype Assay , 2004, Cancer biology & therapy.
[135] C. Béroud,et al. Human Splicing Finder: an online bioinformatics tool to predict splicing signals , 2009, Nucleic acids research.
[136] Doron Betel,et al. The microRNA.org resource: targets and expression , 2007, Nucleic Acids Res..
[137] R. Brandão,et al. Characterisation of unclassified variants in the BRCA1/2 genes with a putative effect on splicing , 2011, Breast Cancer Research and Treatment.
[138] Eva Dizin,et al. Negative feedback loop of BRCA1-BARD1 ubiquitin ligase on estrogen receptor alpha stability and activity antagonized by cancer-associated isoform of BARD1. , 2010, The international journal of biochemistry & cell biology.
[139] D. D. Bailey,et al. Yeast Screens Identify the RNA Polymerase II CTD and SPT5 as Relevant Targets of BRCA1 Interaction , 2008, PloS one.
[140] T. Ouchi,et al. Autoubiquitination of the BRCA1·BARD1 RING Ubiquitin Ligase* , 2002, The Journal of Biological Chemistry.
[141] J. Rodriguez,et al. Cytoplasmic mislocalization of BRCA1 caused by cancer-associated mutations in the BRCT domain. , 2004, Experimental cell research.